Genomic Enterprise

 

Led innovation and research initiatives in biotech/tech for both undergraduate and graduate programs (staff of 2,000 and 20,000 students) focused on generating IP and facilitating Technology Transfer (TT) and Licensing of products & solutions. Provided direction to multidisciplinary team of 40+ people (technical, PhD, Post-Doctoral and professors). Instrumental in increasing number of Institutional patents from zero to 40 in two years, including two licensed to different sectors.



Main Patents:

 

Method and System to Share Information about Diseases, US Patent, 2014. Patent was licensed non-exclusively to different corporations.

 

Process of obtaining monoclonal anti-ADAM33 and their use in molecular identification of breast cancer,  BR Patent, 2018. Patent licensed to Thermo Fisher Scientific USA (NYSE:TMO) for both mice and human mAbs; Participated indirectly.

 

Applications of the peptide Peligipeptin for Cancer Treatment. BR Patent Pending, 2018.